(NASDAQ: MRSN) Mersana Therapeutics's forecast annual revenue growth rate of 12.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Mersana Therapeutics's revenue in 2025 is $34,769,000.On average, 5 Wall Street analysts forecast MRSN's revenue for 2025 to be $120,445,361, with the lowest MRSN revenue forecast at $94,074,544, and the highest MRSN revenue forecast at $135,746,822. On average, 4 Wall Street analysts forecast MRSN's revenue for 2026 to be $364,570,051, with the lowest MRSN revenue forecast at $59,888,304, and the highest MRSN revenue forecast at $1,060,022,981.
In 2027, MRSN is forecast to generate $92,327,802 in revenue, with the lowest revenue forecast at $59,888,304 and the highest revenue forecast at $124,767,300.